sorafenib and yttrium-90 radioembolization for the treatment of advanced HCC

http://www.current-oncology.com/index.php/oncology/article/view/2827/2272

This was in Canada and of course BTG Theraspheres. No reason to consider SRX will be any different.
This is a full access article.

Below is the section I like   - my bold.

Very small numbers but one hell of a result on OS in this select small group.
Overall Survival

The median overall survival for the entire cohort of 40 patients was 11.9 months (iqr: 6.2–18.7 months). The 29 patients who received the sorafenib–⁹⁰Y combination therapy experienced a median overall survival of 12.4 months (Figure 4). Patients who did not proceed to ⁹⁰Y therapy trended toward a lower median overall survival of 5.3 months (iqr: 3.7–22.8 months), p = 0.5924.